A 2-in-1 adaptive design to seamlessly expand a selected dose from a phase 2 trial to a phase 3 trial for oncology drug development

Autor: Zhang, Pingye, Li, Xiaoyun Nicole, Lu, Kaifeng, Wu, Chengqing
Zdroj: In Contemporary Clinical Trials November 2022 122
Databáze: ScienceDirect